BILLERICA, Mass. --(BUSINESS WIRE)--Oct. 2, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D.

Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 30, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 19, 2024-- Quanterix Corporation   (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr.

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 8, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024 . “Our research business once again delivered

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 6, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside

BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 31, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T.

Quanterix improves on its best-in-class p-Tau 217 standalone test with new multi-marker approach reducing the number of patients receiving uncertain results BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 17, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue , and Chief Financial Officer, Vandana Sriram , will attend the

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 5, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare